#Miami #biopharmaceuticals #Hong Kong #Healthcare Conference #Akeso Inc.

Akeso's Upcoming Presentations at Global Healthcare Conferences

Akeso, Inc., a prominent player in the biopharmaceutical sector, has recently announced its participation in two significant upcoming healthcare events scheduled in Miami: the Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference. These events are crucial platforms for healthcare leaders and innovators to discuss advancements and trends in the industry.

Event Details

Akeso will take part in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, starting at 8:45 AM ET. Following this, the company will engage in another fireside chat on Thursday, December 5, 2024, at the Citi 2024 Global Healthcare Conference, scheduled from 8:45 AM to 9:25 AM ET. These discussions will provide valuable insights into Akeso's ongoing research and development efforts, as well as its innovative drug pipeline.

For those unable to attend in person, live streams of Akeso's presentations at the Evercore conference can be accessed online, allowing wider audiences to partake in the conversation surrounding biopharmaceutical advancements.

About Akeso

Founded in 2012, Akeso, Inc. (HKEX: 9926.HK) has rapidly established itself as a leading biopharmaceutical firm. The company is dedicated to the research, development, manufacturing, and commercialization of innovative biological medicines that aim to make a significant impact on global healthcare. Akeso boasts a unique, integrated approach to research and development, leveraging its comprehensive end-to-end drug development platform known as the ACE Platform and advanced technologies, including its proprietary Tetrabody bispecific antibody development.

With a robust pipeline featuring over 50 innovative drug candidates across various therapeutic areas—including cancer, autoimmune diseases, and metabolic disorders—Akeso is at the forefront of biopharmaceutical research. Notably, 22 candidates are currently undergoing clinical trials, and 5 new drugs are commercially available, with additional new drugs awaiting regulatory approval across multiple indications.

The company's commitment to affordable patient care is evident through its goal of developing first-in-class and best-in-class therapies. By integrating superior global resources, Akeso aims to drive breakthrough research and development that delivers value to patients and stakeholders alike.

Stay updated with Akeso's journey and find more information at Akeso's Corporate Profile or follow them on social media platforms like LinkedIn and X (formerly Twitter).

These upcoming conferences represent a great opportunity for Akeso to showcase its innovative solutions and commitment to advancing healthcare, bolstering its reputation as a global leader in the biopharmaceutical industry.